Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May-Jun;34(3):1445-1449.
doi: 10.21873/invivo.11927.

Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study

Evangelos Paraskevaidis  1 , Antonios Athanasiou  2 , Maria Paraskevaidi  2 , Evripidis Bilirakis  3 , Georgios Galazios  4 , Emmanuel Kontomanolis  4 , Konstantinos Dinas  5 , Aristotelis Loufopoulos  5 , Maria Nasioutziki  5 , Ioannis Kalogiannidis  6 , Apostolos Athanasiadis  6 , Alexios Papanikolaou  5 , Anastasia Vatopoulou  7 , Gregorios Grimbizis  7 , Dimitrios Tsolakidis  7 , Alexandros Daponte  8 , George Valasoulis  8 , Stella Gritzeli  9 , Georgios Michail  10 , Georgios Adonakis  10 , Minas Paschopoulos  11 , Orestis Tsonis  11 , Maria-Eugenia Anaforidou  11 , Anna Batistatou  12 , Maria Kyrgiou  2 ; HeCPA (Hellenic Cervical Pathology Academic) Group
Affiliations

Cervical Pathology Following HPV Vaccination in Greece: A 10-year HeCPA Observational Cohort Study

Evangelos Paraskevaidis et al. In Vivo. 2020 May-Jun.

Abstract

Background: In Greece the population-level impact of HPV vaccination is unknown due to lack of official registries. This study presents in a pragmatic frame the comparison of cervical pathology data between HPV-vaccinated and unvaccinated women referred for colposcopy.

Patients and methods: This is an observational prospective cohort study performed in 7 academic Obstetrics and Gynaecology Departments across Greece between 2009-2019. Cases were women that had completed HPV vaccination before coitarche and were referred for colposcopy due to abnormal cytology. For each vaccinated woman an unvaccinated matched control was selected.

Results: A total of 849 women who had been vaccinated before coitarche and 849 unvaccinated controls were recruited. The combination of cytological, colposcopic and molecular findings necessitated treatment in only a single case among vaccinated (0.1%) and in 8.4% among unvaccinated.

Conclusion: HPV vaccination at a proper age can markedly reduce development of severe cervical precancers and consequently the need for treatment, as well as their long-term related obstetrical morbidity.

Keywords: HPV; vaccination; vaccine.

PubMed Disclaimer

Conflict of interest statement

The Authors have nothing to disclose.

References

    1. Gustafsson L, Pontén J, Bergström R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71(2):159–165. doi: 10.1002/(sici)1097-0215(19970410)71:2<159::aid-ijc6>3.0.co;2-#. - DOI - PubMed
    1. Lăără E, Day NE, Hakama M. Trends in mortality from cervical cancer in the nordic countries: Association with organised screening programmes. (London, England) Lancet. 1987;1(8544):1247–1249. doi: 10.1016/s0140-6736(87)92695-x. - DOI - PubMed
    1. Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in australia: A modelling study. Lancet Public Health. 2019;4(1):e19–e27. doi: 10.1016/S2468-2667(18)30183-X. - DOI - PubMed
    1. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069. doi: 10.1002/14651858.CD009069.pub3. - DOI - PMC - PubMed
    1. Drolet M, Benard E, Perez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509. doi: 10.1016/s0140-6736(19)30298-3. - DOI - PMC - PubMed

MeSH terms

Substances